Matthew J McLaughlin1, Eric Caliendo, Ryan Lowder, William D Watson, Brad Kurowski, Katherine T Baum, Laura S Blackwell, Christine H Koterba, Kristen R Hoskinson, Sarah J Tlustos, Kanecia O Zimmerman, Sudhin A Shah, Stacy J Suskauer. 1. Division of Pediatric Rehabilitation Medicine, Children's Mercy Kansas City, Kansas City, Missouri (Dr McLaughlin); University of Missouri-Kansas City School of Medicine (Dr McLaughlin); Weill Cornell School of Medicine, New York City, New York (Mr Caliendo); David Geffen School of Medicine at UCLA, Los Angeles, California (Mr Lowder); Blythedale Children's Hospital, Valhalla, New York (Drs Watson and Shah); Department of Rehabilitation and Regenerative Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York City, New York (Dr Watson); Departments of Pediatrics and Neurology and Rehabilitation Medicine, Division of Pediatric Rehabilitation Medicine, Cincinnati Children's Hospital Medical Center, and Departments of Pediatrics and Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio (Dr Kurowski); Children's Hospital of Philadelphia, Philadelphia, Pennsylvania (Dr Baum); Department of Neuropsychology, Children's Healthcare of Atlanta, Atlanta, Georgia (Dr Blackwell); Department of Pediatric Psychology and Neuropsychology, Nationwide Children's Hospital, Columbus, Ohio (Dr Koterba); The Ohio State University College of Medicine, Columbus (Drs Koterba and Hoskinson); Center for Biobehavioral Health, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio (Dr Hoskinson); Department of Rehabilitation, Children's Hospital Colorado and Department of Physical Medicine and Rehabilitation, University of Colorado Anschutz Medical Campus, Aurora, Colorado (Dr Tlustos); Department of Pediatrics, Division of Critical Care Medicine, Department of Pediatrics, Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina (Dr Zimmerman); Department of Rehabilitation Medicine, Weill Cornell Medicine, New York, New York (Dr Shah); Kennedy Krieger Institute, Baltimore, Maryland (Dr Suskauer); and Departments of Physical Medicine & Rehabilitation and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland (Dr Suskauer).
Abstract
OBJECTIVES: To describe dosing practices for amantadine hydrochloride and related adverse effects among children and young adults with traumatic brain injury (TBI) admitted to pediatric inpatient rehabilitation units. SETTING: Eight pediatric acute inpatient rehabilitation units located throughout the United States comprising the Pediatric Brain Injury Consortium. PARTICIPANTS: Two-hundred thirty-four children and young adults aged 2 months to 21 years with TBI. DESIGN: Retrospective data revie. MAIN OUTCOME MEASURES: Demographic variables associated with the use of amantadine, amantadine dose, and reported adverse effects. RESULTS: Forty-nine patients (21%) aged 0.9 to 20 years received amantadine during inpatient rehabilitation. Forty-five percent of patients admitted to inpatient rehabilitation with a disorder of consciousness (DoC) were treated with amantadine, while 14% of children admitted with higher levels of functioning received amantadine. Children with DoC who were not treated with amantadine were younger than those with DoC who received amantadine (median 3.0 vs 11.6 years, P = .008). Recorded doses of amantadine ranged from 0.7 to 13.5 mg/kg/d; the highest total daily dose was 400 mg/d. Adverse effects were reported in 8 patients (16%); nausea/abdominal discomfort and agitation were most common, each reported in 3 patients. The highest reported dose without an adverse effect was 10.1 mg/kg/d. CONCLUSION: During pediatric inpatient rehabilitation, amantadine was prescribed to children across a range of ages and injury severity and was most commonly prescribed to older children with DoC. Dosing varied widely, with weight-based dosing for younger/smaller children at both lower and higher doses than what had been previously reported. Prospective studies are needed to characterize the safety and tolerability of higher amantadine doses and optimize amantadine dosing parameters for children with TBI.
OBJECTIVES: To describe dosing practices for amantadine hydrochloride and related adverse effects among children and young adults with traumatic brain injury (TBI) admitted to pediatric inpatient rehabilitation units. SETTING: Eight pediatric acute inpatient rehabilitation units located throughout the United States comprising the Pediatric Brain Injury Consortium. PARTICIPANTS: Two-hundred thirty-four children and young adults aged 2 months to 21 years with TBI. DESIGN: Retrospective data revie. MAIN OUTCOME MEASURES: Demographic variables associated with the use of amantadine, amantadine dose, and reported adverse effects. RESULTS: Forty-nine patients (21%) aged 0.9 to 20 years received amantadine during inpatient rehabilitation. Forty-five percent of patients admitted to inpatient rehabilitation with a disorder of consciousness (DoC) were treated with amantadine, while 14% of children admitted with higher levels of functioning received amantadine. Children with DoC who were not treated with amantadine were younger than those with DoC who received amantadine (median 3.0 vs 11.6 years, P = .008). Recorded doses of amantadine ranged from 0.7 to 13.5 mg/kg/d; the highest total daily dose was 400 mg/d. Adverse effects were reported in 8 patients (16%); nausea/abdominal discomfort and agitation were most common, each reported in 3 patients. The highest reported dose without an adverse effect was 10.1 mg/kg/d. CONCLUSION: During pediatric inpatient rehabilitation, amantadine was prescribed to children across a range of ages and injury severity and was most commonly prescribed to older children with DoC. Dosing varied widely, with weight-based dosing for younger/smaller children at both lower and higher doses than what had been previously reported. Prospective studies are needed to characterize the safety and tolerability of higher amantadine doses and optimize amantadine dosing parameters for children with TBI.
Authors: Gabriel C Araujo; Tanya N Antonini; Vicki Anderson; Kathryn A Vannatta; Christina G Salley; Erin D Bigler; H Gerry Taylor; Cynthia Gerhardt; Kenneth Rubin; Maureen Dennis; Warren Lo; Mark T Mackay; Anne Gordon; Christine Hajek Koterba; Alison Gomes; Mardee Greenham; Keith Owen Yeates Journal: J Int Neuropsychol Soc Date: 2017-05-15 Impact factor: 2.892
Authors: Joseph T Giacino; Douglas I Katz; Nicholas D Schiff; John Whyte; Eric J Ashman; Stephen Ashwal; Richard Barbano; Flora M Hammond; Steven Laureys; Geoffrey S F Ling; Risa Nakase-Richardson; Ronald T Seel; Stuart Yablon; Thomas S D Getchius; Gary S Gronseth; Melissa J Armstrong Journal: Arch Phys Med Rehabil Date: 2018-08-08 Impact factor: 3.966
Authors: Peter D Patrick; James A Blackman; Jennifer L Mabry; Marcia L Buck; Matthew J Gurka; Mark R Conaway Journal: J Child Neurol Date: 2006-10 Impact factor: 1.987
Authors: Andrea Loggini; Ruth Tangonan; Faten El Ammar; Ali Mansour; Fernando D Goldenberg; Christopher L Kramer; Christos Lazaridis Journal: Clin Neurol Neurosurg Date: 2020-03-21 Impact factor: 1.876
Authors: Stephanie Gorman; Marcia A Barnes; Paul R Swank; Mary Prasad; Charles S Cox; Linda Ewing-Cobbs Journal: Neuropsychology Date: 2015-07-27 Impact factor: 3.295